

**Anti-PSGL1 / CD162 Reference Antibody (neihulizumab)  
Recombinant Antibody  
Catalog # APR10713**

**Specification**

---

**Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">Q14242</a>
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG4
Calculated MW	145.72 KDa

**Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) - Additional Information**

**Target/Specificity**  
PSGL1 / CD162

**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) - Protein Information**

**Name** SELPLG

**Function**  
A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. Critical for the initial leukocyte capture.

**Cellular Location**  
Membrane; Single-pass type I membrane protein.

**Tissue Location**


Expressed on neutrophils, monocytes and most lymphocytes

### Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)

### Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) - Images



Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-PSGL1 / CD162 Reference Antibody (neihulizumab) is more than 99.48%, determined by SEC-HPLC.